Piperacillin-Tazobactam vs Cefoxitin Prophylaxis for Pancreatoduodenectomy

被引：0
|
作者：
Yang, Ziyi [1 ]
Mei, Jiawei [1 ]
Gong, Wei [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Dept Gen Surg, Xinhua Hosp, Sch Med, Shanghai, Peoples R China
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2023年 / 330卷 / 11期
关键词：
D O I：
10.1001/jama.2023.12773
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1098 / 1098
页数：1
相关论文
共 50 条
  • [21] Strategies for Updating Piperacillin-Tazobactam Breakpoints
    Bobenchik, April M.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2023, 61 (04)
  • [22] HAEMOLYTIC ANAEMIA CAUSED BY PIPERACILLIN-TAZOBACTAM
    Dapper, I.
    Nauwynck, M.
    Selleslag, D.
    Hidajat, M.
    Bourgeois, M.
    Martens, P.
    Wilmer, A.
    ACTA CLINICA BELGICA, 2009, 64 (06) : 517 - 519
  • [23] EEG Abnormalities in Patients with Suspected Encephalopathy Receiving Cefepime vs Piperacillin-Tazobactam
    Alshaikh, Jumana
    Pettit, Natasha
    Rangarajan, Aditi
    Pisano, Jennifer
    Issa, Naoum
    NEUROLOGY, 2020, 94 (15)
  • [24] Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations
    Liu, Q
    Rand, K
    Derendorf, H
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (05) : 494 - 497
  • [25] Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam
    Alosaimy, Sara
    Lagnf, Abdalhamid M.
    Hobbs, Athena L., V
    Mubarez, Musa
    Kufel, Wesley D.
    Morrisette, Taylor
    Polisetty, Radhika S.
    Li, David
    Veve, Michael P.
    Simon, Sam P.
    Truong, James
    Finch, Natalie
    Venugopalan, Veena
    Rico, Matthew
    Amaya, Lee
    Yost, Christine
    Cubillos, Ashley
    Chandler, Elisabeth
    Patch, Megan
    Smith, Ian Murphy Kelsey
    Biagi, Mark
    Wrin, Justin
    Moore, W. Justin
    Molina, Kyle C.
    Rebold, Nicholas
    Holger, Dana
    Coyne, Ashlan J. Kunz
    Jorgensen, Sarah
    Witucki, Paige
    Tran, Nikki N.
    Davis, Susan L.
    Sakoulas, George
    Rybak, Michael J.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E1444 - E1455
  • [26] Cefepime vs Piperacillin-Tazobactam for Acute Infection in Hospitalized Adults-Reply
    Qian, Edward T.
    Semler, Matthew W.
    Rice, Todd W.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (08):
  • [27] ACTIVITY OF CP 99,219 COMPARED WITH THOSE OF CIPROFLOXACIN, GREPAFLOXACIN, METRONIDAZOLE, CEFOXITIN, PIPERACILLIN, AND PIPERACILLIN-TAZOBACTAM AGAINST 489 ANAEROBES
    SPANGLER, SK
    JACOBS, MR
    APPELBAUM, PC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (10) : 2471 - 2476
  • [28] Cystic Fibrosis and Piperacillin-tazobactam: Adverse Reactions
    Diab Caceres, Layla
    Celeste Marcos, Maria
    Giron Moreno, Rosa Maria
    ARCHIVOS DE BRONCONEUMOLOGIA, 2015, 51 (12): : 664 - 665
  • [29] Reevaluating Piperacillin-Tazobactam Mortality-Reply
    Chanderraj, Rishi
    Dickson, Robert P.
    Sjoding, Michael W.
    JAMA INTERNAL MEDICINE, 2024, 184 (10) : 1269 - 1269
  • [30] Piperacillin-Tazobactam Penetration into Human Pancreatic Juice
    Minelli, Elisa Bertazzoni
    Benini, Anna
    Franco, Luigina
    Bassi, Claudio
    Pederzoli, Paolo
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (11) : 4149 - 4152
12345